Company: IMCR
Filing Date: 2025-05-07
Form Type: 10-Q
Source: 0001671927-25-000009
Chunk: 17

Company: Immunocore Holdings plc
Filing Date: 2025-05-07
Form: 10-Q
Item: Part I, Item 1
Chunk 17
---
761)Accumulated other comprehensive loss(33,090)(33,763)Total shareholders' equity378,479 360,716 Total liabilities and shareholders' equity$1,028,008 $1,009,506 

The accompanying notes form an integral part of these condensed consolidated financial statements.

2

Table of Contents

 Immunocore Holdings plc

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)

(Unaudited) (In thousands, except share and per share data)

Three Months Ended March 31,20252024Revenue:Revenue from sale of therapies, net$93,881 $70,342 Collaboration revenue— 160 Total revenue93,881 70,502 Cost and operating expenses:Cost of revenue from sale of therapies(831)(246)Research and development expense(56,468)(57,459)Selling, general and administrative expense(40,198)(39,287)Loss from operations(3,616)(26,490)Other income (expense):Interest income4,176 8,246 Interest expense(3,025)(3,239)Foreign currency gain (loss)3,080 (2,406)Other income (expense), net5,469 (190)Net income (loss) before income taxes6,084 (24,079)Income tax expense(1,061)(357)Net income (loss)$5,023 $(24,436)Other comprehensive income:Exchange differences on translation of foreign operations673 897 Total comprehensive income (loss)$5,696 $(23,539)Basic net income (loss) per share$0.10 $(0.49)Basic weighted-average number of shares outstanding50,086,684 49,877,218 Diluted net income (loss) per share$0.10 $(0.49)Diluted weighted-average number of shares outstanding51,949,798 49,877,218 

The accompanying notes form an integral part of these condensed consolidated financial statements.

3

Table of Contents

Immunocore Holdings plc

Condensed Consolidated Statements of Shareholders’ Equity

(Unaudited) (In thousands, except share data)

Ordinary SharesDeferred SharesAdditional Paid-in  CapitalAccumulateddeficitAccumulated other comprehensive  (loss) incomeTotal Shareholders' EquitySharesAmountSharesAmountAs of December 31, 202450,064,860$135